Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation

Narendranath Epperla(University of Utah), Veronika Bachanová(University of Minnesota), Dheeraj Kodali(West Virginia University), Parameswaran Hari(Medical College of Wisconsin), Fiona He(Allina Health), Abraham S. Kanate(HonorHealth), Timothy S. Fenske(Medical College of Wisconsin), Michael Craig(Edith Cowan University), Marcelo C. Pasquini(Cleveland Clinic), Kwang Woo Ahn(Medical College of Wisconsin), Ariel Kleman(Medical College of Wisconsin), Mehdi Hamadani(Medical College of Wisconsin)
Transplantation and Cellular Therapy
February 2, 2018
10.1016/j.bbmt.2018.01.015
Cited by 5

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2015|740
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718